HK1220692A1 - 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物 - Google Patents

作為布羅莫結構域抑制劑的苯並咪唑酮衍生物

Info

Publication number
HK1220692A1
HK1220692A1 HK16108876.4A HK16108876A HK1220692A1 HK 1220692 A1 HK1220692 A1 HK 1220692A1 HK 16108876 A HK16108876 A HK 16108876A HK 1220692 A1 HK1220692 A1 HK 1220692A1
Authority
HK
Hong Kong
Prior art keywords
bromodomain inhibitors
benzimidazolone derivatives
benzimidazolone
derivatives
bromodomain
Prior art date
Application number
HK16108876.4A
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Gregory Chin
Britton Kenneth Corkey
Jinfa Du
Kristyna Elbel
Robert H Jiang
Tetsuya Kobayashi
Ruben Martinez
Samuel E Metobo
Michael Mish
Sophie Shevick
David Sperandio
Hai Yang
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1220692A1 publication Critical patent/HK1220692A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16108876.4A 2013-03-28 2016-07-25 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物 HK1220692A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
HK1220692A1 true HK1220692A1 (zh) 2017-05-12

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108876.4A HK1220692A1 (zh) 2013-03-28 2016-07-25 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物

Country Status (35)

Country Link
US (2) US9255089B2 (zh)
EP (1) EP2978759B1 (zh)
JP (1) JP6339175B2 (zh)
KR (1) KR101847698B1 (zh)
CN (1) CN105102453B (zh)
AP (1) AP2015008741A0 (zh)
AU (1) AU2014241152B2 (zh)
BR (1) BR112015024078A2 (zh)
CA (1) CA2907502C (zh)
CL (1) CL2015002871A1 (zh)
CR (1) CR20150515A (zh)
CY (1) CY1119165T1 (zh)
DK (1) DK2978759T3 (zh)
EA (1) EA029497B1 (zh)
ES (1) ES2626397T3 (zh)
HK (1) HK1220692A1 (zh)
HR (1) HRP20170750T1 (zh)
HU (1) HUE034772T2 (zh)
IL (1) IL241186A0 (zh)
LT (1) LT2978759T (zh)
MD (1) MD4531C1 (zh)
MX (1) MX2015013798A (zh)
MY (1) MY176634A (zh)
NZ (1) NZ711586A (zh)
PE (1) PE20151982A1 (zh)
PH (1) PH12015502246A1 (zh)
PL (1) PL2978759T3 (zh)
PT (1) PT2978759T (zh)
RS (1) RS56050B1 (zh)
SG (1) SG11201507926RA (zh)
SI (1) SI2978759T1 (zh)
TW (1) TWI530499B (zh)
UY (1) UY35516A (zh)
WO (1) WO2014160873A1 (zh)
ZA (1) ZA201506356B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2118074B1 (en) 2007-02-01 2014-01-22 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
ES2755827T3 (es) 2013-03-15 2020-04-23 Incyte Holdings Corp Heterciclos tricíclicos como inhibidores de proteína BET
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
CN105492439B (zh) 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Betタンパク質阻害剤としての三環式複素環
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
AU2015333689A1 (en) 2014-10-14 2017-05-25 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
WO2017114843A1 (en) 2015-12-29 2017-07-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Xanthine derivative inhibitors of bet proteins
CN114366748A (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
US20180179191A1 (en) * 2016-11-22 2018-06-28 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
US11180510B2 (en) 2017-11-06 2021-11-23 Centre National De La Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
MX2020006612A (es) 2017-12-20 2020-11-09 Betta Pharmaceuticals Co Ltd Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
JP7394140B2 (ja) * 2019-02-02 2023-12-07 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド 標的ユビキチン化分解brd4タンパク質化合物、その調製方法および応用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
AU2020360170A1 (en) 2019-09-30 2022-05-19 Kyowa Kirin Co., Ltd. Bet degrader
US20230183215A1 (en) * 2020-05-21 2023-06-15 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
KR102307566B1 (ko) * 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제

Also Published As

Publication number Publication date
HUE034772T2 (en) 2018-02-28
WO2014160873A1 (en) 2014-10-02
KR20150135476A (ko) 2015-12-02
CN105102453A (zh) 2015-11-25
MD20150104A2 (ro) 2016-02-29
EP2978759B1 (en) 2017-03-15
DK2978759T3 (da) 2017-06-19
AP2015008741A0 (en) 2015-09-30
CR20150515A (es) 2015-12-01
BR112015024078A2 (pt) 2017-07-18
UY35516A (es) 2014-09-30
ZA201506356B (en) 2017-08-30
JP2016515584A (ja) 2016-05-30
PL2978759T3 (pl) 2017-08-31
US20160031868A1 (en) 2016-02-04
CN105102453B (zh) 2018-04-06
EA029497B1 (ru) 2018-04-30
CA2907502A1 (en) 2014-10-02
EP2978759A1 (en) 2016-02-03
PE20151982A1 (es) 2016-01-28
SG11201507926RA (en) 2015-10-29
EA201591455A1 (ru) 2016-01-29
MD4531B1 (ro) 2017-11-30
JP6339175B2 (ja) 2018-06-06
CL2015002871A1 (es) 2016-05-13
RS56050B1 (sr) 2017-09-29
ES2626397T3 (es) 2017-07-24
AU2014241152A1 (en) 2015-09-17
MD4531C1 (ro) 2018-06-30
TW201504233A (zh) 2015-02-01
SI2978759T1 (sl) 2017-05-31
KR101847698B1 (ko) 2018-04-10
PH12015502246A1 (en) 2016-02-01
IL241186A0 (en) 2015-11-30
MY176634A (en) 2020-08-19
NZ711586A (en) 2016-09-30
TWI530499B (zh) 2016-04-21
CA2907502C (en) 2018-02-27
US20140296246A1 (en) 2014-10-02
MX2015013798A (es) 2016-02-16
PT2978759T (pt) 2017-05-31
US9255089B2 (en) 2016-02-09
HRP20170750T1 (hr) 2017-07-28
AU2014241152B2 (en) 2016-11-03
LT2978759T (lt) 2017-05-25
CY1119165T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
HK1220692A1 (zh) 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
IL256946B (en) Bromodomain inhibitors
HK1224297A1 (zh) 布羅莫結構域抑制劑
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
HK1223090A1 (zh) -氮雜吲哚衍生物